Biotech · Private company

EpicentRx, Inc.

Track this companyFree. Adds EpicentRx, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials142 recruiting or active

Pipeline programs31From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline31

Cisplatin/carboplatin plus etoposidePhase 3 · Carcinoma, Small Cell LungClinicalTrials.gov · fetched Nov 12, 2026
RRx-001 + eLOOP DevicePhase 3 · Carcinoma, Small Cell LungClinicalTrials.gov · fetched Nov 12, 2026
AdAPT-001Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
CarboplatinPhase 2 · Small Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Checkpoint Inhibitor, ImmunePhase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
CisplatinPhase 2 · Small Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Cisplatin for injectionPhase 2 · Oral MucositisClinicalTrials.gov · fetched Nov 12, 2026
Cisplatin for injection 100 mg/m2Phase 2 · Oral MucositisClinicalTrials.gov · fetched Nov 12, 2026
EtoposidePhase 2 · Small Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Gemcitabine and cisplatinPhase 2 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Intensity Modulated Radiation Therapy (IMRT)Phase 2 · Oral MucositisClinicalTrials.gov · fetched Nov 12, 2026
IrinotecanPhase 2 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
IrinotecanPhase 2 · Small Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Radiation TherapyPhase 2 · Oral MucositisClinicalTrials.gov · fetched Nov 12, 2026
RegorafenibPhase 2 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
RRx-001Phase 2 · Oral MucositisClinicalTrials.gov · fetched Nov 12, 2026
RRx-001Phase 2 · Small Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
RRx-001Phase 2 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
RRx-001Phase 2 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
VinorelbinePhase 2 · Small Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Fixed dose Temozolomide (75 mg/m2)Phase 1 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
IrinotecanPhase 1 · Brain Tumor, RecurrentClinicalTrials.gov · fetched Nov 12, 2026
IrinotecanPhase 1 · Malignant Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
NivolumabPhase 1 · Malignant Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
RadiationPhase 1 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
RRx-001Phase 1 · Malignant Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
RRx-001Phase 1 · Brain Tumor, RecurrentClinicalTrials.gov · fetched Nov 12, 2026
RRx-001 + WBRTPhase 1 · Brain MetastasesClinicalTrials.gov · fetched Nov 12, 2026
RRx-001 dose escalation with TMZ + RTPhase 1 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
TemozolomidePhase 1 · Brain Tumor, RecurrentClinicalTrials.gov · fetched Nov 12, 2026
TMZ MaintenancePhase 1 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials14

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 2, 2024ClinicalTrials.gov NCT05966194 · fetched Nov 12, 2026
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System TumorsPHASE1 · TERMINATED · started Jan 26, 2023ClinicalTrials.gov NCT04525014 · fetched Nov 12, 2026
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung CancerPHASE3 · UNKNOWN · started Aug 1, 2022ClinicalTrials.gov NCT05566041 · fetched Nov 12, 2026
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 29, 2021ClinicalTrials.gov NCT04673942 · fetched Nov 12, 2026
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung CancerPHASE3 · TERMINATED · started Dec 24, 2018ClinicalTrials.gov NCT03699956 · fetched Nov 12, 2026
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral CancersPHASE2 · COMPLETED · started Jul 12, 2018ClinicalTrials.gov NCT03515538 · fetched Nov 12, 2026
RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic GliomasPHASE1 · COMPLETED · started Feb 14, 2017ClinicalTrials.gov NCT02871843 · fetched Nov 12, 2026
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)PHASE1 · TERMINATED · started Aug 30, 2016ClinicalTrials.gov NCT02801097 · fetched Nov 12, 2026
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and NivolumabPHASE1 · COMPLETED · started Jul 21, 2015ClinicalTrials.gov NCT02518958 · fetched Nov 12, 2026
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line TherapyPHASE2 · TERMINATED · started Jul 16, 2015ClinicalTrials.gov NCT02452970 · fetched Nov 12, 2026
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)PHASE2 · COMPLETED · started Jun 1, 2015ClinicalTrials.gov NCT02489903 · fetched Nov 12, 2026
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain MetastasesPHASE1 · COMPLETED · started Feb 6, 2015ClinicalTrials.gov NCT02215512 · fetched Nov 12, 2026
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal CancerPHASE2 · COMPLETED · started May 1, 2014ClinicalTrials.gov NCT02096354 · fetched Nov 12, 2026
Safety and Pharmacokinetic Study of RRx-001 in Cancer SubjectsPHASE1 · COMPLETED · started Sep 1, 2011ClinicalTrials.gov NCT01359982 · fetched Nov 12, 2026